Evidence map›Paper›PMID 38054729›Full record

ArticlemBio2024

An

Kristina E Atanasoff, Luca Brambilla, Daniel C Adelsberg, Shreyas Kowdle, Christian S Stevens, Stefan Slamanig, Chuan-Tien Hung, Yanwen Fu, Reyna Lim, Linh Tran and 6 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in mBio, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

  • Update of
    An2023
5 · Who and what money

Authors and funding

16 authors at 3 institutions in 2 countries.

Kristina E AtanasoffDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.ORCID 0000-0002-1025-4640
Luca BrambillaDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Daniel C AdelsbergDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Shreyas KowdleDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Christian S StevensDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Stefan SlamanigDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Chuan-Tien HungDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Yanwen FuSorrento Therapeutics, Inc., San Diego, California, USA.
Reyna LimSorrento Therapeutics, Inc., San Diego, California, USA.
Linh TranSorrento Therapeutics, Inc., San Diego, California, USA.
Robert AllenSorrento Therapeutics, Inc., San Diego, California, USA.
Weina SunDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.ORCID 0000-0002-2435-5047
J Andrew DutyDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Goran BajicDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.ORCID 0000-0003-0480-4324
Benhur LeeDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.ORCID 0000-0003-0760-1709
Domenico TortorellaDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.ORCID 0000-0003-0961-3535
Icahn School of Medicine at Mount Sinai · USSorrento Therapeutics (United States) · USUniversity of Amsterdam · NL

Funding

NCCAT: National Center for CryoEM Access and Training- Supplement for Windows 10 and FFIU24GM129539 · NIGMS · NEW YORK STRUCTURAL BIOLOGY CENTER · PI DE MARCO, ALEX, KIEFT, JEFFREY S · 2018 to 2023
$53.9M
TRAINING PROGRAM: MECHANISMS OF VIRUS-HOST INTERACTIONST32AI007647 · NIAID · MOUNT SINAI SCHOOL OF MEDICINE OF NYU · PI Domenico Tortorella · 2000 to 2026
$11.5M
Mount Sinai Medical Scientist Training ProgramT32GM146636 · NIGMS · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Talia H Swartz · 2022 to 2026
$6.8M
SYSTEMATIC DRUG REPURPOSING TARGETING IMMUNE ACTIVATION NETWORKS IN ALZHEIMER'S DISEASE (AD)RF1AG059319 · NIA · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI EHRLICH, MICHELLE E, GANDY, SAMUEL E. · 2018 to 2018
$4.2M
Structural interrogation of vaccine- and infection-induced B cell responsesR01AI168178 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Goran Bajic · 2022 to 2026
$3.9M
Identification of human cytomegalovirus life cycle stage-specific therapeuticsR01AI139258 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI TORTORELLA, DOMENICO · 2019 to 2022
$1.6M
Delineating the mechanism and inhibitory capacity of CMV neutralizing antibodiesR21AI147632 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI TORTORELLA, DOMENICO · 2020 to 2021
$465k
NIAID NIH HHS R01 AI139258NIAID NIH HHS R01 AI168178NIAID NIH HHS R21 AI147632NIAID NIH HHS T32 AI007647NIA NIH HHS RF1 AG059319NIGMS NIH HHS T32 GM146636NIGMS NIH HHS U24 GM129539
6 · The paper itself

Abstract

importanceThe COVID-19 pandemic remains a significant public health concern for the global population; the development and characterization of therapeutics, especially ones that are broadly effective, will continue to be essential as severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) variants emerge. Neutralizing monoclonal antibodies remain an effective therapeutic strategy to prevent virus infection and spread so long as they recognize and interact with circulating variants. The epitope and binding specificity of a neutralizing anti-SARS-CoV-2 Spike receptor-binding domain antibody clone against many SARS-CoV-2 variants of concern were characterized by generating antibody-resistant virions coupled with cryo-EM structural analysis and VSV-spike neutralization studies. This workflow can serve to predict the efficacy of antibody therapeutics against emerging variants and inform the design of therapeutics and vaccines.

Indexed as

COVID-19PandemicsAntibodies, NeutralizingAntibodies, ViralEpitopesHumansSARS-CoV-2Spike Glycoprotein, CoronavirusAntibodies, NeutralizingAntibodies, ViralEpitopesSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2cryo-EMepitope mappingneutralizing antibodySARS-CoV-2structural analysisviral resistance

Identifiers

PMID38054729
PMCPMC10870823
OpenAlexW4389397348

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.